Insights
Search Results
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.
Client Highlights
11.06.24
Wilson Sonsini Advises PrognomiQ on Patent Matters Related to $34 Million Series D
On November 5, 2024, PrognomiQ, a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, announced the succesful completion of a $34 million Series D financing. The round was led by Seer with participation from Catalio Capital Management, aMoon, Invus, and Bruker. Wilson Sonsini Goodrich & Rosati advised PrognomiQ on patent matters related to the transaction.
Client Highlights
10.10.24
Wilson Sonsini Advises on Patent Matters Related to Verona’s FDA Approval
On June 26, 2024, Verona Pharma announced that the U.S. Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters.
News Articles
9.17.24
Wilson Sonsini, Attorneys Recognized in 2024 Edition of LMG Life Sciences
On September 17, 2024, LMG Life Sciences recognized several Wilson Sonsini practices and 19 of its attorneys in the 2024 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012.
News Articles
6.06.24
Wilson Sonsini Practices, Attorneys Named in 2024 Chambers USA Guide
Wilson Sonsini Goodrich & Rosati practices and attorneys were honored in the recently published 2024 edition of Chambers USA: America's Leading Lawyers for Business. This year, the firm was ranked in 36 geography-specific practice categories, while 79 attorneys were honored among the best in their fields.
Client Highlights
5.29.24
Wilson Sonsini Advises Radar Therapeutics on IP Matters Related to $13.4 Million Seed Funding
On May 23, 2024, Radar Therapeutics, a biotech company developing smart programmable medicines, announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related to the transaction.
News Articles
5.24.24
Wilson Sonsini Sponsors National Inventors Hall of Fame Induction Ceremony
On May 9, 2024, the National Inventors Hall of Fame held its annual Induction Ceremony in Washington, D.C., to celebrate the latest class of inductees who have made exceptional contributions to society. Wilson Sonsini Goodrich & Rosati was a visionary sponsor of the event, which was hosted in partnership with the United States Patent and Trademark Office. Sir Shankar Balasubramanian, founder of Solexa (acquired by Illumina in 2007) and firm client Biomodal, was honored among the 2024 inductees. Numerous Wilson Sonsini patents and innovation practitioners were in attendance, including partners Vern Norviel, Lou Lieto, Ali Alemozafar, and Derrick Rowe; senior patent counselor Bruce Kisliuk; and senior counsel Jeff Seidel, as well as chief licensing advisor Kathy Ku.
Client Highlights
5.06.24
Wilson Sonsini Advises Karius on IP Matters Related to $100 Million Series C
On May 2, 2024, Karius®, Inc. (Karius), a world leader in genomic diagnostics for infectious disease, announced the successful completion of a $100 million Series C financing. Khosla Ventures, along with new investors 5AM Ventures and Gilde Healthcare, co-led the round. New investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others also participated. Wilson Sonsini Goodrich & Rosati advised Karius on IP matters related to the transaction.
Client Highlights
10.31.23
Firm Advises Verve Therapeutics on IP Matters Related to Expansion of Lilly Relationship
On October 31, 2023, Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the expansion of its relationship with Eli Lilly and Company (Lilly) to include Verve’s in vivo gene editing programs targeting PCSK9 and ANGPTL3. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
9.28.23
Wilson Sonsini Advises Adela on Patent Matters Related to $48 Million Financing
On September 25, 2023, Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced the completion of a $48 million financing. The round includes existing investors F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor Labcorp. Wilson Sonsini Goodrich & Rosati advised Adela on patent matters related to the transaction.
Client Highlights
8.31.23
Wilson Sonsini Pro Bono Client Revive & Restore Successfully Advocates for New Vaccine Testing Alternative to Horseshoe Crab Blood
On August 22, 2023, the U.S. Pharmacopeia (USP) announced a long-awaited new regulatory chapter, known as Chapter <86>, which provides guidance on endotoxin testing using recombinant Factor C (rFC), a synthetic alternative to blood cells extracted from endangered horseshoe crabs. rFC can be developed at scale and eliminates the need for harvesting (bleeding) horseshoe crabs. The chapter reinforces the work of Wilson Sonsini client Revive & Restore, whose science-based campaign highlighted the efficacy and safety of the recombinant product for endotoxin testing.